Webinar | November 12, 2026

From Testing To Launch: A Single-Source Approach For mAbs

The rapid expansion of monoclonal antibodies (mAbs) is shifting therapeutic delivery toward highly concentrated formulations, larger injection volumes, and patient self-administration. Bringing these sensitive biologics to market requires overcoming critical development hurdles, including maintaining formulation stability, verifying drug-container compatibility, and ensuring consistent device performance across the product lifecycle. Pairing advanced containment—such as large-volume syringes and cartridges—with patient-centric delivery platforms like the Aidaptus® autoinjector and Vertiva® on-body delivery system helps address these demands early. By integrating analytical testing, engineering, and manufacturing under a coordinated, single-source strategy with Stevanato Group, biopharma teams can streamline compatibility assessments, reduce supply chain complexity, and accelerate commercialization.

Watch the full webinar to examine real-world strategies for mitigating mAb development risks and building reliable, patient-ready combination products.

Access The Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Drug Delivery Leader? Subscribe today.

Subscribe to Drug Delivery Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Drug Delivery Leader